S
Sally P. Stenning
Researcher at Medical Research Council
Publications - 99
Citations - 11978
Sally P. Stenning is an academic researcher from Medical Research Council. The author has contributed to research in topics: Cancer & Testicular cancer. The author has an hindex of 38, co-authored 98 publications receiving 10817 citations. Previous affiliations of Sally P. Stenning include University of Manchester & Emory University.
Papers
More filters
Journal ArticleDOI
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada,Sally P. Stenning,Rhian Gabe,L.C. Thompson,David Levy,R. Rampling,Sara Erridge,Frank Saran,Rao Gattamaneni,Kirsten Hopkins,Sarah Beall,V. Peter Collins,Siow-Ming Lee +12 more
TL;DR: Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5- day schedule in this setting, which challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
Journal ArticleDOI
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Graham M. Mead,Sharon L. Barrans,Wendi Qian,Jan Walewski,John Radford,Max Wolf,S Clawson,Sally P. Stenning,Claire L. Yule,Andrew Jack +9 more
TL;DR: The observed differences in outcome and other clinical features validate the proposed diagnostic criteria for sporadic Burkitt lymphoma and evaluate the efficacy of dose-modified CODOX-M/IVAC in patients diagnosed using these criteria.
Journal ArticleDOI
Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis
Valerie Catherine Brueton,Jayne F. Tierney,Sally P. Stenning,Sarah Meredith,Seeromanie Harding,Irwin Nazareth,Greta Rait +6 more
TL;DR: Most of the trials evaluated questionnaire response rather than ways to improve participants return to site for follow-up, and there is no good evidence that the following strategies impact on trial response/retention.
Journal ArticleDOI
Randomized Trial of Two or Five Computed Tomography Scans in the Surveillance of Patients With Stage I Nonseminomatous Germ Cell Tumors of the Testis: Medical Research Council Trial TE08, ISRCTN56475197—The National Cancer Research Institute Testis Cancer Clinical Studies Group
Gordon J. S. Rustin,Graham M. Mead,Sally P. Stenning,Paul Vasey,Nina Aass,Robert Huddart,M. Sokal,Jonathan K. Joffe,S. J. Harland,SJ Kirk +9 more
TL;DR: This study can rule out with 95% probability an increase in the proportion of patients relapsing with intermediate- or poor-prognosis disease of more than 1.6% if they have two rather than five CT scans as part of their surveillance protocol.
Journal ArticleDOI
A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.
Graham M. Mead,Norman M. Bleehen,Anna Gregor,Jill Bullimore,D. Shirley Murrell,R. Rampling,J. Trevor Roberts,M.G. Glaser,Peter L. Lantos,James W. Ironside,Tim H. Moss,Michael Brada,Jill B. Whaley,Sally P. Stenning +13 more
TL;DR: The role of chemotherapy in the treatment of patients with primary central nervous system lymphoma (PCL) remains unclear, with no randomized trials available to aid in the interpretation of the current data.